Hidradenitis Suppurativa Treatment Market Size, Share, Growth, Trends, and Global Industry Analysis: Treatment Type (Medication, Biologics, Antibiotics, Hormonal Therapy, Immune Suppurativa Drugs, Zinc Supplements, Pain Medications, Surgery) Route of Administration (Oral, Tropical) End User (Hospitals, Homecare, Specialty Clinics) Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) and Region Forecast 2020-2031

Hidradenitis Suppurativa Treatment Market size was valued at US$ XX in 2024 and is projected to reach US$ XX million by 2031 at a CAGR of XX% from 2025-2031. Moreover, the U.S. Hidradenitis Suppurativa Treatment Market is projected to grow significantly, reaching an estimated value of US$ XX Million by 2031.

The market for treatment of hidradenitis suppurativa (HS) is an overall global market dedicated to controlling and reducing the symptoms of hidradenitis suppurativa, a chronic inflammatory skin disease involving painful nodules, abscesses, and scarring that usually develops in those areas of skin that rub against each other.

The market for the treatment of hidradenitis suppurativa (HS) is being driven by higher awareness and diagnosis rates, growing prevalence of chronic inflammatory dermatoses, and expanding demand for precision therapies like biologics and immunomodulators. Breakthroughs in clinical research, FDA approvals of new treatments such as IL-17 inhibitors, and increased access to dermatological services particularly through telemedicine are also speeding up market growth. Yet, the market is constrained by limited options for very severe cases, exorbitant expenses with biologics, and diagnostic delay from overlapping symptoms of other dermatological conditions. The chronic, recurrent character of HS generally triggers patient non-adherence and treatment fatigue, which can disrupt long-term therapeutic success.

Facts & Figures

• HS affects approximately 1%-4% of people in the U.S. and disproportionately impacts people from racial and ethnic minority groups.
• Approximately 33% to 40% of individuals with hidradenitis suppurativa report an affected first-degree relative, suggesting a hereditary component with an autosomal dominant transmission pattern.
• The condition's onset is commonly between puberty and 40 years, most frequently from ages 21 to 29.
• Women are about 3 times more affected than men.

 Key Developments

• In August 2024, ACELYRIN announced plans to complete ongoing trials of Izokibep and suspend new investment in hidradenitis suppurativa and psoriatic arthritis.
• In June 2024, UCB’s BIMZELX (bimekizumab) was approved by the UK's Medicines and Healthcare products Regulatory Agency (MHRA) to treat adults with active moderate-to-severe hidradenitis suppurativa.
• In May 2024, MoonLake Immunotherapeutics announced that the first patients have been screened at a US trial site in its global Phase III clinical program, VELA, evaluating sonelokimab, an investigational Nanobody designed for moderate-to-severe hidradenitis suppurativa.

Hidradenitis Suppurativa Treatment Market Segmentation

Based on the treatment type

• Medication
• Biologics
• Antibiotics
• Hormonal Therapy
• Immune Suppurativa Drugs
• Zinc Supplements
• Pain Medications
• Surgery

Given their targeted mechanism in reducing inflammation and preventing flares, the HS treatment market is dominated by biologics. Substantial control of moderate to severe HS symptoms has only been observed with TNF-alpha inhibitors and interleukin inhibitors. Unlike antibiotics or hormonal therapy, biologics can help manage symptoms over the long-term with less likelihood of relapse. Regulatory approvals for innovative biologic therapies coupled with rising investment levels in research and development are driving segment growth. In addition, an increasing awareness of biologics among patients and their effectiveness in enhancing the quality of life is driving adoption rates.

Based on the end users

• Hospitals
• Homecare
• Specialty Clinics

Hospitals are a commanding end-user segment because of their capacity to treat cases of HS of a moderate to severe nature that tend to call for multidisciplinary therapy. These institutions are prepared to provide the complete gamut of treatments ranging from systemic antibiotics and biologics to surgery such as incision, drainage, or wide excision. Hospitals are also primary sites for clinical trials and administration of biologic therapy, especially in patients with close monitoring needs or comorbid conditions. Availability of dermatologists, high-tech diagnostic equipment, and inpatient facilities renders hospitals the site of choice for complicated or recalcitrant cases of HS. Hospitals also tend to be at the forefront of introducing new treatment standards and embracing digital health technologies like teledermatology, which further consolidates their position in early detection and tailored delivery of care.

Based on the route of administration

• Oral
• Tropical

Oral therapies are key in the management of mild to moderate HS, especially in early cases or flare-ups. Oral treatments of choice often involve antibiotics like tetracyclines and clindamycin that suppress inflammation and bacterial burden. Hormonal therapies, particularly anti-androgens, are also given orally to treat HS in patients with hormonal disorders. In more refractory or severe cases, systemic inflammation can be controlled with oral immunosuppressants such as corticosteroids or cyclosporine. Oral dosing convenience favors improved patient compliance, particularly in an outpatient population. Side effects or loss of efficacy, however, may ultimately limit long-term use, and treatment progresses to biologics or combinations in more advanced cases. With ongoing advances in research, more newer oral drugs with selective inflammatory pathways are being researched, promising to provide better targeted and more tolerable treatment strategies.

Based on the distribution channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Hospital pharmacies have a key role in the delivery of sophisticated therapies for moderate to severe HS, most notably biologics and immunosuppressants with tight clinical monitoring. Such facilities are frequently the first point of access to new treatments, especially those that are given by injection or infusion. Hospital pharmacies also facilitate inpatient treatment and post-operative care and are therefore critical to the management of complex or recalcitrant HS patients. Their alignment with dermatology departments and clinical trials networks provides integrated access to experimental drugs and tailored treatment protocols. Furthermore, hospital pharmacies are aided by institutional reimbursement systems, which may enhance affordability and compliance for costly treatments. Hospital pharmacies are likely to remain a foundation of HS care delivery as biologic adoption increases and treatment recommendations change.